The hottest financial report for the third quarter

Financial report for the third quarter of 2010: Bayer's sales and earnings rose again

sales increased by 16.1%, reaching 8.581 billion euros

without exception, the current EBITDA increased by 10.5%, reaching 1.656 billion euros

core earnings per share increased by 21.8%, reaching 0.95 euros

withdrawal of litigation reserves of 436 million euros

net financial liabilities decreased by 1.6 billion euros, Up to 9.1 billion euros

the group's 2010 expectation was determined

Shanghai, from October 28, 2010 to the third quarter of 2010, Bayer Group's sales and basic income increased significantly. "We are very happy that the results of the third quarter are better than last year, and we are full of confidence in 2010," said Malkin, chairman of Bayer Group Management Committee Dr. marijn Dekkers said when he released the third quarter interim financial report on Thursday. Bayer materials technology has made outstanding contributions to the good development of its business from July to September. Bayer crop science also achieved growth in sales and improved its operating performance. Bayer healthcare's sales remained stable, with revenue slightly lower than the same period last year. Exchange rate has a positive impact on earnings, especially for medical and health care and crop science

in the third quarter, Bayer Group's sales increased by 16.1% to 8.581 billion euros (in the third quarter of 2009, sales were 7.392 billion euros). After adjustment of currency and asset portfolio, the business increased by 8.4%. Excluding exceptions, current EBITDA increased by 10.5% to € 1656 million (the third quarter of 2009 was € 1499 million). This increase was mainly attributed to the sharp rise in revenue of materials technology and the favorable monetary impact. Excluding exceptions, current EBIT increased by 18.5% to € 992 million (Q3 2009:

the health care consumer goods business in all regions achieved growth

in the third quarter, Bayer healthcare's sales increased by 8.5% to 4.271 billion euros (3.936 billion euros in the third quarter of 2009). After currency and portfolio adjustment (exchange rate and portfolio adjustment), the business increased by 0.9%

the sales of pharmaceutical business increased by 7.2% (0.0% after currency and portfolio adjustment) to 2.732 billion euros. Strong business expansion in emerging markets. However, the medical reform in some countries has affected the business, and the business in North America has fallen sharply. This is mainly due to the decline in sales of Yaz series oral contraceptives due to the competition of generic drugs in the United States. Excluding the sales of Yaz series oral contraceptives in the United States, the revenue of the pharmaceutical sector increased by 4.4% over the same period last year (after exchange rate and portfolio adjustment). Among the high-end products of the Department, menyuele, an intrauterine device that releases hormones, performed particularly well, and its sales increased by 20.7% after currency adjustment (exchange rate adjustment). Hemophilia drug baikeqi also achieved a strong growth of more than 6.9% (after exchange rate adjustment). Aspirin, a cardiovascular and cerebrovascular disease drug to prevent myocardial infarction, increased by more than 12.8% (after exchange rate adjustment), and Elida, an erectile dysfunction drug, increased by more than 9.4% (after exchange rate adjustment). The sales of betaferon/betaseron with multiple sclerosis increased by 1.2% (after exchange rate adjustment)

in the third quarter, the sales of the health consumer goods sector increased by 10.9% (2.6% after the adjustment of exchange rate and portfolio), reaching 1.539 billion euros, and all regions contributed to this growth. The performance of the over-the-counter drug business (health consumer products) is satisfactory, especially in North America. Among its high-end products, one-a-day, a dietary supplement product, achieved the largest sales growth, with an increase of more than 20.3% (after exchange rate adjustment). The analgesics aleve and aspirin increased by 18.2% and 3.4% respectively after currency adjustment. Skin products bepanthen/bepanthol increased by 14.3% (after exchange rate adjustment). The healthcare sector has also been affected by the negative development of the U.S. diabetes care market, which has inhibited the sales of blood glucose monitoring system byankang. The overall sales of this product line fell by 6.5% (after exchange rate adjustment). The animal health sector benefited from many factors, including the success of advantage, a flea, tick and worm control product, whose sales increased by 7.5% (after exchange rate adjustment)

Bayer healthcare's current EBITDA without exceptions fell by 3.7% to € 1099 million (Q3 2009:. R & D expenditure also increased. However, these factors were partially offset by positive monetary effects

crop protection business grew steadily in the third quarter

with the improvement of the market environment, crop science sales in the third quarter increased by 17.6% (8.3% after the adjustment of exchange rate and asset portfolio), reaching 1.341 billion euros (1.14 billion euros in the third quarter of 2009). Due to the significant reduction of inventory in the distribution channels and the rising prices of agricultural raw materials, demand has increased significantly. The selling price is about the same as that of the same quarter last year

the sales of crop protection business to create good materials in China increased by 16.1% (7.4% after exchange rate adjustment), reaching 1.13 billion euros. The business of fungicides, pesticides and herbicides achieved good growth, but the sales of seed treatment products decreased, especially in France and Germany. With the good performance of each business unit, the sales of crop protection business in North America increased by 49.1% compared with the same quarter of last year, which was exceptionally weak (after the adjustment of exchange rate and additional options). In addition, sales in Asia Pacific and Latin America/Africa/Middle East also increased by 5.2% (after exchange rate adjustment) and 6.8% (after exchange rate adjustment) respectively. However, in Europe, sales fell by 3.1% (after exchange rate adjustment)

the sales of environmental science and life sciences business increased by 26.3% (13.5% after exchange rate and portfolio adjustment), reaching 211 million euros. Sales of the environmental science business unit decreased by 3.5% (after exchange rate adjustment), mainly due to the decline in product sales for individual consumers in the United States due to adverse weather conditions. The sales of the bioscience business unit increased by 52.7% (after exchange rate and portfolio adjustment), mainly due to the strong growth of the vegetable seed business. The sales of cotton, rapeseed and rice increased significantly, which eventually contributed to the growth of this business

without exception, the current EBITDA of crop science increased by 16.7% to 126 million euros (108million euros in the third quarter of 2009), which is mainly due to the strong growth of crop protection business and positive monetary effect, which largely offset the increased R & D expenses of life science

sales and revenue of materials technology increased significantly

high tech materials business achieved significant growth compared with the same quarter of last year. The poor performance of last year was mainly attributed to the poor economic environment. Sales of materials technology increased by 30.8% (23.0% after exchange rate adjustment) to 2.665 billion euros (2.038 billion euros in the third quarter of 2009). The growth of business is mainly due to the demand growth of major customer industries. In addition, the overall selling price of the company has also increased significantly

due to the sales growth of all products and regions, the foam raw material (polyurethane) business increased by 22.7% (after exchange rate adjustment), of which the sales growth in the Asia Pacific region was the largest. The European region has also achieved a similar growth trend, and last year, the region was under great pressure due to the economic crisis. High tech plastics (polycarbonate) business has also made great progress, with sales increased by 28.7% (after exchange rate adjustment). The sales of coatings, adhesives and special chemicals raw materials business increased by 17.6% (after exchange rate adjustment). This is mainly due to the growth in sales of all products and regions, especially in the Asia Pacific region and Europe

the current EBITDA of Bayer Material Technology Group, excluding exceptions, increased significantly to € 409 million (the third quarter of 2009 was € 238 million). This good performance is mainly attributed to the significant increase in sales volume, the improvement of selling price and efficiency. In contrast, by designing a cup-shaped grinding wheel, the cost of raw materials increases, and the income decreases to a certain extent

litigation reserves in the United States

third quarter earnings decreased by 436 million euros due to special expenses (191 million euros in the third quarter of 2009). This is mainly related to litigation in the United States. Of this expenditure, 386million euros is related to crop science, mainly used to solve the litigation related to genetically modified rice (ll rice). The special cost of medical care is 50million euros, which is mainly used for defense costs related to yaz/yasmin lawsuit. Bayer Group's profit after interest and tax decreased by 13.9% to 556million euros (646million euros in the third quarter of 2009)

non operating results (-267million euros) were at the same level as the same period last year (third quarter of 2009: - 262million euros). The tax expense in the third quarter was only 4million euros (Q3 2009: 135million euros plus), mainly due to the regional income distribution. Net income increased by 12.4% to EUR 280million (EUR 249million in the third quarter of 2009). Core earnings per share increased by 21.8% to € 0.95 (Q3 2009:

total cash flow decreased by 25.0% year-on-year to 879 million euros (1.172 billion euros in the third quarter of 2009). However, this is mainly due to litigation related provisions that are not reflected in net cash flow. Net cash flow increased by 2.5% to € 1555 million (the third quarter of 2009 was € 1517 million). Net financial liabilities decreased significantly in the third quarter of 2010 - from € 10.7 billion to € 9.1 billion

note: the reprinted content is indicated with the source. The reprint is for the purpose of transmitting more information, and does not mean to agree with its views or confirm the authenticity of its content